drugset / Trial / NCT00362115

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

NCT00362115

Phase 2 Completed 449 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.

Timeline

Start
2006-05
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan medoxomil Other / unclassified 5 mg Oral
Subject Azilsartan medoxomil Other / unclassified 10 mg Oral
Subject Azilsartan medoxomil Other / unclassified 20 mg Oral
Subject Azilsartan medoxomil Other / unclassified 40 mg Oral
Subject Azilsartan medoxomil Other / unclassified 80 mg Oral
Comparator Olmesartan Other / unclassified 20 mg Oral

Indications